ALERT

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Pilot Study of Osmotic-Release Methylphenidate (OROS-MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD)

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD. The study involved 255 participants, recruited from six sites.

CTN Protocol ID:

CTN-0029

DSMB ID:

DSMB-0029

Status:

Completed

ClinicalTrials.gov ID:

Principal Investigator(s)

Eugene Somoza, M.D., Ph.D

University of Cincinnati/Cin ARC

3210 Jefferson Avenue, Suite 6
Cincinnati, OH 45220
United States

Somoza@carc.uc.edu

T. John Winhusen, Ph.D.

Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division

University of Cincinnati

Addiction Sciences Division

3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
United States

winhust@ucmail.uc.edu

Participating Sites

Maryhaven, Inc., Ohio
Mayo Clinic, Minnesota
VA New York Harbor Healthcare System, New York
New York State Psychiatric Institute, New York
Kaiser Permanente, Center for Health Research